Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Other Names for this Disease
  • Amebic dysentery
  • Amoebiasis due to Entamoeba histolytica
  • Amoebic dysentery due to Entamoeba histolytica
  • Intestinal amebiasis
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Amebiasis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Tinidazole
Trade Name
(Manufacturer Name)
Tindamax®
(Mission Pharmacal)
Indication
The FDA has approved this product to be used in this manner.
Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage.
More Information about this product Drug Information Portal